Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
US12077785B2 · kind B2 · utility
0Cited by
12References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 14, 2019 |
| Grant date | Sep 3, 2024 |
| Priority date | — |
| Expiry date | Dec 11, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/14043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.